Hint mode is switched on Switch off
For swift navigation between sections

Dendreon
LEI 549300C0XK81HDI8KK82

The issuer's bonds defaulted in 2015
Organization name
Dendreon Corporation
Country name
USA
Country of registration
USA
Industry
Miscellaneous Healthcare: Products and Services
Public debt
540 mln USD
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Quotes

Request sent
Access denied
Quotes provided by information providers are indicative in nature

Profile

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer.

Awards

Documentation

Stocks

Latest issues

Public debt by currencies

Codes

  • LEI
    549300C0XK81HDI8KK82
  • NACE
    *** ***
  • NAICS
    *** ***
Registration is required to get access.